Hypoxia inducible factor-1: a novel target for cancer therapy - PubMed (original) (raw)
Review
Hypoxia inducible factor-1: a novel target for cancer therapy
Vladimir E Belozerov et al. Anticancer Drugs. 2005 Oct.
Abstract
Hypoxia develops in the majority of solid tumors due to the inability of the existing vascular system to supply the growing tumor mass with adequate amounts of oxygen. A large body of clinical evidence suggests that intratumoral hypoxia correlates with the elevated aggressive behavior of cancer cells and their resistance to therapy, leading to poor patient prognoses. A heterodimeric transcription factor, hypoxia inducible factor-1 (HIF-1), has been shown to orchestrate a large number of molecular events required for the adaptation of tumor cells to hypoxia. Therefore, HIF-1 has become an attractive target for the development of anti-cancer drugs. Here, we highlight some of the recently developed small-molecule inhibitors of HIF-1 function. These drugs disrupt the HIF-1 signaling pathway through a variety of mechanisms, including the inhibition of HIF-1alpha protein synthesis, stabilization, nuclear translocation and HIF-1 transactivation of target genes.
Similar articles
- Inhibitors of hypoxia-inducible factor-1 signaling.
Belozerov VE, Van Meir EG. Belozerov VE, et al. Curr Opin Investig Drugs. 2006 Dec;7(12):1067-76. Curr Opin Investig Drugs. 2006. PMID: 17209524 Review. - A novel approach to cancer therapy using PX-478 as a HIF-1α inhibitor.
Lee K, Kim HM. Lee K, et al. Arch Pharm Res. 2011 Oct;34(10):1583-5. doi: 10.1007/s12272-011-1021-3. Arch Pharm Res. 2011. PMID: 22076756 Review. - Design and synthesis of novel small-molecule inhibitors of the hypoxia inducible factor pathway.
Mooring SR, Jin H, Devi NS, Jabbar AA, Kaluz S, Liu Y, Van Meir EG, Wang B. Mooring SR, et al. J Med Chem. 2011 Dec 22;54(24):8471-89. doi: 10.1021/jm201018g. Epub 2011 Nov 23. J Med Chem. 2011. PMID: 22032632 Free PMC article. - New drugs target hypoxia response in tumors.
Garber K. Garber K. J Natl Cancer Inst. 2005 Aug 3;97(15):1112-4. doi: 10.1093/jnci/dji261. J Natl Cancer Inst. 2005. PMID: 16077066 No abstract available. - Targeting NF-κB and HIF-1 pathways for the treatment of cancer: part II.
Wilczynski J, Duechler M, Czyz M. Wilczynski J, et al. Arch Immunol Ther Exp (Warsz). 2011 Aug;59(4):301-7. doi: 10.1007/s00005-011-0132-3. Epub 2011 May 28. Arch Immunol Ther Exp (Warsz). 2011. PMID: 21625847 Review.
Cited by
- HIF-1α-induced expression of the m6A reader YTHDF1 inhibits the ferroptosis of nucleus pulposus cells by promoting SLC7A11 translation.
Lu X, Li D, Lin Z, Gao T, Gong Z, Zhang Y, Wang H, Xia X, Lu F, Song J, Xu G, Jiang J, Ma X, Zou F. Lu X, et al. Aging Cell. 2024 Sep;23(9):e14210. doi: 10.1111/acel.14210. Epub 2024 May 23. Aging Cell. 2024. PMID: 38783692 Free PMC article. - Curcumol β-cyclodextrin inclusion complex enhances radiosensitivity of esophageal cancer under hypoxic and normoxic condition.
Su M, Ren X, Du D, He H, Zhang D, Xie R, Deng X, Zou C, Zou H. Su M, et al. Jpn J Radiol. 2023 Nov;41(11):1275-1289. doi: 10.1007/s11604-023-01446-7. Epub 2023 May 25. Jpn J Radiol. 2023. PMID: 37227584 Free PMC article. - Topotecan is a potent inhibitor of SUMOylation in glioblastoma multiforme and alters both cellular replication and metabolic programming.
Bernstock JD, Ye D, Gessler FA, Lee YJ, Peruzzotti-Jametti L, Baumgarten P, Johnson KR, Maric D, Yang W, Kögel D, Pluchino S, Hallenbeck JM. Bernstock JD, et al. Sci Rep. 2017 Aug 7;7(1):7425. doi: 10.1038/s41598-017-07631-9. Sci Rep. 2017. PMID: 28785061 Free PMC article. - Examining the structure-activity relationship of benzopyran-based inhibitors of the hypoxia inducible factor-1 pathway.
Ferguson J, De Los Santos Z, Devi N, Van Meir E, Zingales S, Wang B. Ferguson J, et al. Bioorg Med Chem Lett. 2017 Apr 15;27(8):1731-1736. doi: 10.1016/j.bmcl.2017.02.073. Epub 2017 Mar 1. Bioorg Med Chem Lett. 2017. PMID: 28285917 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources